The EU Commission accepts commitments from a pharmaceutical company to address excessive pricing (Aspen)

On 10 February 2021, the European Commission accepted commitments from Aspen under Article 9(1) of Regulation 1/2003, concluding a three year investigation into suspected excessive pricing practices affecting six critical cancer medicines. What you need to know - key takeawaysThe Commission based its assessment of pricing levels on the absolute and relative profitability of the medicines; considering Aspen's costs as well as profit levels of other similar businesses in the pharmaceutical industry.The Commission also considered the lack of potential justifications for price and profit levels; in this case the

L'accès à cet article est réservé aux abonnés

Déjà abonné ? Identifiez-vous

L’accès à cet article est réservé aux abonnés.

Lire gratuitement un article

Vous pouvez lire cet article gratuitement en vous inscrivant.